Samad Muhammadnejad
Overview
Explore the profile of Samad Muhammadnejad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ashraf H, Kosari F, Khorsand A, Muhammadnejad S, Mansouri V, Muhammadnejad A, et al.
Arch Iran Med
. 2025 Feb;
27(12):683-692.
PMID: 39891456
Background: Xenogeneic graft-versus-host disease (xGvHD) is an inevitable confounder of preclinical evaluation of adoptive immunotherapies on tumor-bearing immunodeficient mouse models. This study was designed to appraise the clinical and histopathological...
2.
Monzavi S, Muhammadnejad S, Mansouri V, Ashraf H, Ahmadbeigi N
Animal Model Exp Med
. 2024 Nov;
8(1):20-29.
PMID: 39601130
Human-derived tumor models are essential for preclinical development of new anticancer drug entities. Generating animal models bearing tumors of human origin, such as patient-derived or cell line-derived xenograft tumors, is...
3.
Ghazvinian Z, Abdolahi S, Ahmadvand M, Emami A, Muhammadnejad S, Aghdaei H, et al.
Bioimpacts
. 2023 Sep;
13(5):383-392.
PMID: 37736341
Introduction: Gastric cancer is one of the most commonly known malignancies and is the fifth cancer-related death globally. Whereas natural killer (NK) cells play a critical role in tumor elimination;...
4.
Monzavi S, Hamidieh A, Vasei M, Ai J, Ahmadbeigi N, Arshadi H, et al.
Bioimpacts
. 2023 Sep;
13(5):415-424.
PMID: 37736339
Introduction: T cells that recognize WT1 peptides have been shown to efficiently eliminate WT1-expressing tumor cells. This study was designed to investigate the feasibility of isolating WT1-reactive T cells from...
5.
Kamyabi R, Jahandideh A, Panahi N, Muhammadnejad S
Iran J Basic Med Sci
. 2023 Mar;
26(3):359-366.
PMID: 36865043
Objectives: Intolerable side effects and resistance to chemotherapeutic drugs have encouraged scientists to develop new methods of drug combinations with fewer complications. This study aimed to investigate the synergistic effects...
6.
Muhammadnejad S, Monzavi S, Torabi-Rahvar M, Sotoudeh M, Muhammadnejad A, Tavakoli-Shiraji S, et al.
Int Immunopharmacol
. 2022 Dec;
114:109446.
PMID: 36463696
Objective: A preclinical study was designed to evaluate the effects of adoptively transferred cytokine-induced killer (CIK) cells on colorectal adenocarcinoma. Methods: Forty NOG mice bearing HT-29 xenograft tumors were developed...
7.
Bitaraf M, Muhammadnejad S, Azimzadeh A, Tanourlouee S, Amini E, Zolbin M, et al.
Animal Model Exp Med
. 2022 Dec;
5(6):575-581.
PMID: 36451547
Background: Bladder cancer poses a great burden on society and its high rate of recurrence and treatment failure necessitates use of appropriate animal models to study its pathogenesis and test...
8.
Nasiri F, Muhammadnejad S, Rahbarizadeh F
Clin Exp Med
. 2022 Nov;
23(6):2535-2549.
PMID: 36434173
Chimeric antigen receptor T cells (CAR T cells) have improved the prognosis of patients with certain hematologic malignancies. However, broader clinical application of this type of therapy is dependent on...
9.
Razzaghdoust A, Muhammadnejad S, Parvin M, Bahram B, Zangeneh M, Basiri A
Iran J Basic Med Sci
. 2022 Aug;
25(7):816-821.
PMID: 36033955
Objectives: To assess the efficacy and safety of T-DM1, as an anti-HER2 antibody-drug conjugate (ADC), alone and in combination with two platinum-based chemotherapy regimens in patient-derived xenografts (PDXs) of muscle-invasive...
10.
Hajighasemlou S, Nikbakht M, Pakzad S, Azadbakht A, Muhammadnejad S, Mirmoghtadaei M, et al.
Vet Med Sci
. 2022 Jul;
8(5):2086-2091.
PMID: 35838746
Background: Hepatocellular carcinoma (HCC) is the fifth most diagnosed cancer and the second leading cause of cancer-related deaths worldwide. Sorafenib is the standard treatment used in the advanced stages of...